Investigators assessed the safety and efficacy of pembrolizumab monotherapy for use in patients with previously treated advanced anal squamous cell carcinoma.
Investigators assessed the efficacy of the addition of oxaliplatin to capecitabine-based postoperative chemoradiotherapy for treating locally advanced rectal cancer.
The BLA submission is supported by data from the phase 2 POD1UM-202 study, which evaluated retifanlimab in patients with locally advanced or metastatic SCAC who progressed after platinum-based chemotherapy.
While anal cancer is relatively uncommon in the general population, its incidence is substantially elevated in certain groups, including patients with HIV and certain autoimmune conditions.
The BLA is supported by data from the POD1UM-202 trial that evaluated retifanlimab in 94 adults with locally advanced or metastatic SCAC who progressed after platinum-based chemotherapy.
As Crohn disease perianal fistulas often do not respond to available treatments, researchers developed a patient-derived quality-of-life tool to evaluate the impact of the condition on patients.
Short-course radiotherapy followed by chemotherapy and total mesorectal excision improved outcomes for patients with high-risk locally advanced rectal cancer.
If the current COVID-19 trends persist, the NCI estimates that the pandemic’s impact could threaten the trend of annually decreasing cancer mortality seen in the US since 1990.
Digital manometry provides similar pressure readings compared with the gold-standard high-resolution anorectal manometry in patients with chronic constipation and fecal incontinence.
Survival and recurrence rates were not significantly different between patients with low rectal cancer who were treated with either local or total mesorectal excision.
